-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Study senior author Marcus Bugt, of the Karolinska Institute in Sweden, said: "In the absence of a protective vaccine, it is important to identify infected people, especially those with asymptomatic or mild illness, who have a strong adaptive immune response to the new coronavirus.
" So far, there have been very few cases of re-infection in patients who have previously been infected with neo-crown pneumonia.
Most studies related to the body's immune protection against neo-coronavirus focus on induction and antibodies, but antibody responses are decreasing and cannot be detected in all patients with neocooprosis, especially those with mild illness.
in mice, the vaccine-induced memory T-cell response can last for years and can resist viruses even without detectable antibodies.
, it is not clear how the neo-coronavirus-specific T-cell response is related to the human antibody response or the clinical process of neo-coronary pneumonia in the human body.
for more information, the Bugt team evaluated the response of more than 200 Swedes to new coronavirus-specific T-cells and antibodies throughout the exposure, infection and development of neocyto pneumonia.
results showed that all 23 patients with severe neo-coronary pneumonia recovered from neo-coronavirus-specific antibodies and T-cell reactions.
but surprisingly, in the months after infection, a neo-coronavirus-specific memory T-cell response was detected in family members exposed to the new coronavirus and in most patients with neo-coronary pneumonia.
addition, only 17 (more than half) of the 28 family members exposed to the virus had detectable antibody reactions, while almost all (26/28) showed T-cell responses.
27 of the 31 patients who recovered from neo-coronary pneumonia had detected antibody responses and 30 had developed T-cell responses.
, they will determine whether a powerful memory T-cell response can prevent new coronary pneumonia in the long term without detectable antibodies, said Mr. Bugt.
.
